Vernalis plc (LON:VER) has earned a consensus recommendation of “Hold” from the seven research firms that are presently covering the stock, reports. Four equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is GBX 39.40 ($0.52).

VER has been the topic of several research analyst reports. RX Securities restated a “buy” rating on shares of Vernalis plc in a report on Monday, August 7th. N+1 Singer reiterated a “hold” rating and issued a GBX 28 ($0.37) price target on shares of Vernalis plc in a report on Monday, August 7th. Stifel Nicolaus decreased their price target on Vernalis plc from GBX 24 ($0.32) to GBX 21 ($0.28) and set a “hold” rating on the stock in a report on Monday, August 7th. Finally, Panmure Gordon reiterated a “hold” rating and issued a GBX 31 ($0.41) price target on shares of Vernalis plc in a report on Monday, August 7th.

WARNING: This report was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at

Shares of Vernalis plc (LON VER) traded down 0.980% during midday trading on Thursday, hitting GBX 12.625. 47,895 shares of the company were exchanged. Vernalis plc has a one year low of GBX 10.00 and a one year high of GBX 39.34. The company’s 50 day moving average price is GBX 14.70 and its 200 day moving average price is GBX 17.79. The firm’s market cap is GBX 66.46 million.

Vernalis plc (LON:VER) last announced its earnings results on Tuesday, September 12th. The company reported GBX (4.10) (($0.05)) EPS for the quarter, topping the consensus estimate of GBX (4.50) (($0.06)) by GBX 0.40 ($0.01). The company had revenue of GBX 2,079 million for the quarter. Vernalis plc had a negative return on equity of 23.94% and a negative net margin of 69.02%. Equities analysts expect that Vernalis plc will post ($5.57) EPS for the current year.

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Analyst Recommendations for Vernalis plc (LON:VER)

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with's FREE daily email newsletter.